Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
The risk of injecting denatured proteins, impurities, or bacterial contamination is extremely high
TRACE provides 10 mg of BPC-157 and 10 mg of TB-500 a total of 50 doses to be used over a 10-week period
Research in dermal wound models shows significantly faster wound closure times, improved wound contraction, and superior cosmetic outcomes with reduced scarring
Contact a qualified healthcare professional for guidance
B12 is stored mainly in the Liver (approx 80%) with a total body store of 2-5mgs in an adult